首页> 外文期刊>Urology >Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder.
【24h】

Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder.

机译:细菌干扰素预防神经源性膀胱尿路感染的多中心随机对照试验。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVES: To compare the effectiveness of bacterial interference versus placebo in preventing urinary tract infection (UTI). METHODS: The main outcome measure was the numbers of episodes of UTI/patient-year. Randomization was computer generated, with allocation concealment by visibly indistinguishable products distributed from a core facility. The healthcare providers and those assessing the outcomes were unaware of the group allocation. Adult patients (n = 65) with neurogenic bladder after spinal cord injury and a history of recurrent UTI were randomized in a 3:1 ratio to receive either Escherichia coli HU2117 or sterile saline. Urine cultures were obtained weekly during the first month and then monthly for 1 year. The patients were evaluable if they remained colonized with E. coli HU2117 for >4 weeks (experimental group). The trial is closed to follow-up. RESULTS: Of the 59 patients who received bladder inoculations, 27 were evaluable (17 in the experimental group and 10 in the placebo group). The 2 study groups had comparable clinical characteristics. Of 17 patients colonized with E. coli HU2117 and the 10 control patients, 5 (29%, 95% confidence interval 0.11-0.56) and 7 (70%, 95% confidence interval 0.35-0.92) developed >1 episode of UTI (P = .049; 1-sided Fisher's exact test), respectively. The average number of episodes of UTI/patient-year was also lower (P = .02, Wilcoxon rank sum test) in the experimental (0.50) than in the control group (1.68). E. coli HU2117 did not cause symptomatic UTI. CONCLUSIONS: Bladder colonization with E. coli HU2117 safely reduces the risk of symptomatic UTI in patients with spinal cord injury. Effective, but less complex, methods for achieving bladder colonization with E. coli HU2117 are under investigation.
机译:目的:比较细菌干扰素和安慰剂在预防尿路感染(UTI)方面的有效性。方法:主要结局指标为UTI /患者年发作次数。随机化是由计算机生成的,通过从核心设施分发的看不清楚的产品来隐藏分配。医疗保健提供者和评估结果的人员不知道小组的分配。脊髓损伤后有神经源性膀胱的成年患者(n = 65)和复发性UTI病史按3:1的比例随机分配,以接受大肠杆菌HU2117或无菌生理盐水。在第一个月每周一次采集尿培养物,然后在一年内每月一次。如果患者在大肠杆菌HU2117上定植> 4周(实验组),则可以评估这些患者。该试验尚未跟进。结果:在接受膀胱接种的59例患者中,有27例是可评估的(实验组17例,安慰剂组10例)。这两个研究组具有可比的临床特征。在定植于大肠杆菌HU2117的17例患者和10例对照患者中,有5例(29%,95%置信区间0.11-0.56)和7例(70%,95%置信区间0.35-0.92)发生了1例UTI(P = .049; 1面Fisher精确检验)。实验组(0.50)的尿路感染/患者年平均发作次数(P = .02,Wilcoxon秩和检验)也低于对照组(1.68)。大肠杆菌HU2117没有引起有症状的UTI。结论:大肠杆菌HU2117膀胱定植可安全降低脊髓损伤患者有症状UTI的风险。目前正在研究有效的但不太复杂的用大肠杆菌HU2117进行膀胱定植的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号